Research

Medical research is an important facet of the medical field and Bellevue ophthalmology clinics are no exception. Our team of researchers is working on several study projects with the goal of advancing ophthalmology treatments in order to provide patients with state-of-the-art care.

Our Active Research Projects

GLK-401-01

GLK-401-01

A prospective, multicenter study of the Glaukos® iStent Infinite trabecular micro-bypass system model IS3 in subjects with mild to moderate primary open-angle glaucoma.

Objective

To evaluate the safety and effectiveness of the Glaukos® iStent infinite Trabecular Micro-Bypass System Model iS3 in adult pseudophakic orphakic subjects with mild to moderate primary open-angle glaucoma (POAG) who have not failed conventional medical and surgical treatment.

Pro00062025

Pro00062025

Alberta Innovates Technology Futures / Nanotechnology application to thetreatment of human eye diseases: pseudoexfoliation syndrome and cataracts.

Objective

To analyze some of the lens capsule tissues that are removed as part of your standard surgery, so that we can better understand mechanisms of eye disease and alert us to potential ways to treat it.

Pro00076087

Pro00076087

Long term results of Hydrus Schlemm canal microstent with or without concomitant phacoemulsification in a variety of glaucoma types and severities.

Objective

To assess the surgical success throughout 5 years postoperatively, and to identify the potential baseline predictors of surgical success.

ILS241-I001 / 0515/0240

ILS241-I001 / 0515/0240

Clareon Toric Single Arm Study (T2-T9).

Objective

The primary objective of this study is to describe mean monocular best corrected distance visual acuity (BCVA) in eyes implanted with Clareon Toric IOLs at 6 months, 1 year and 3 years.

LT4032-301

LT4032-301

Efficacy and safety assessment of T4032 (unpreserved bimatoprost 0.01%) versus Lumigan® 0.01% in ocular hypertensive or glaucomatous patients.

Objective

To find out about the safety and efficacy of T4032, which is a preservative-free formulation of bimatoprost (0.01%) for the treatment of glaucoma or ocular (eye) hypertension.

INFI-103-COMP

INFI-103-COMP

A prospective, randomized, controlled, comparative multicenter clinical study of Glaukos® trabecular micro-bypass system model iS3 Infinite® vs. Hydrus® in adult subjects with primary open-angle glaucoma (POAG).

Objective

To evaluate and compare the safety and effectiveness of two medical devices that are implanted into the eye to reduce eye pressure in people with your condition.

Pro00049690

Pro00049690

Alcon, Outcomes of Vivity EDOF IOL Implantation in Patients with Well Controlled OAG or OHT.

Objective

To evaluate the safety and performance of the Vivity extended depth of focus (EDOF) Intraocular Lens in subjects with well controlled open angle glaucoma (OAG) or ocular hypertension (OHT) who receive this IOL in both eyes.

Pro00065922

Pro00065922 (CEQUA™)

Evaluating the safety and efficacy of nanomicellar cyclosporin 0.09% (CEQUA™) in patients with dry eye disease refractory to emulsion cyclosporin 0.05%.

Objective

The purpose of this study is to see whether participants with DED who have tried the oily 0.05% cyclosporin drop and not noticed an improvement will see an improvement with CEQUA™.

PMCS-002

PMCS-002

Clinical outcomes of Patients bilaterally implanted with the commercially available RxSight Light Adjustable Lens (LAL).

Objective

The purpose of this research is to collect vision results of participants who have been implanted with the commercially available RxSight LAL in both eyes.